308 related articles for article (PubMed ID: 19917368)
1. Long-term experience of plasmapheresis in antibody-mediated rejection in renal transplantation.
Brown CM; Abraham KA; O'Kelly P; Conlon PJ; Walshe JJ
Transplant Proc; 2009 Nov; 41(9):3690-2. PubMed ID: 19917368
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
3. Impact of rituximab therapy for treatment of acute humoral rejection.
Kaposztas Z; Podder H; Mauiyyedi S; Illoh O; Kerman R; Reyes M; Pollard V; Kahan BD
Clin Transplant; 2009; 23(1):63-73. PubMed ID: 19200217
[TBL] [Abstract][Full Text] [Related]
4. High-dose intravenous immunoglobulin and rituximab treatment for antibody-mediated rejection after kidney transplantation: a cost analysis.
Tanriover B; Wright SE; Foster SV; Roush KS; Castillo-Lugo JA; Fa K; Levy FL; Mejia A
Transplant Proc; 2008 Dec; 40(10):3393-6. PubMed ID: 19100397
[TBL] [Abstract][Full Text] [Related]
5. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience.
Jin MK; Cho JH; Kwon O; Hong KD; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
Transplant Proc; 2012 Jan; 44(1):200-3. PubMed ID: 22310614
[TBL] [Abstract][Full Text] [Related]
6. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection.
Hardinger KL; Murillo D
Clin Transpl; 2011; ():401-8. PubMed ID: 22755438
[TBL] [Abstract][Full Text] [Related]
7. Multimodal therapy with combined plasmapheresis, photoapheresis, and intravenous immunoglobulin for acute antibody-mediated renal transplant rejection: a 2-year follow-up.
Lai Q; Pretagostini R; Gozzer M; Cinti P; Meo D; Vita F; Shafii Bafti M; Poli L; Novelli G; Rossi M; Girelli G; Berloco PB
Transplant Proc; 2011 May; 43(4):1039-41. PubMed ID: 21620047
[TBL] [Abstract][Full Text] [Related]
8. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience.
Thielke JJ; West-Thielke PM; Herren HL; Bareato U; Ommert T; Vidanovic V; Campbell-Lee SA; Tzvetanov IG; Sankary HN; Kaplan B; Benedetti E; Oberholzer J
Transplantation; 2009 Jan; 87(2):268-73. PubMed ID: 19155983
[TBL] [Abstract][Full Text] [Related]
9. Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies.
Gupta G; Abu Jawdeh BG; Racusen LC; Bhasin B; Arend LJ; Trollinger B; Kraus E; Rabb H; Zachary AA; Montgomery RA; Alachkar N
Transplantation; 2014 Jun; 97(12):1240-6. PubMed ID: 24937198
[TBL] [Abstract][Full Text] [Related]
10. Plasmapheresis and intravenous immunoglobulin in early antibody-mediated rejection of the renal allograft: a single-center experience.
Slatinska J; Honsova E; Burgelova M; Slavcev A; Viklicky O
Ther Apher Dial; 2009 Apr; 13(2):108-12. PubMed ID: 19379149
[TBL] [Abstract][Full Text] [Related]
11. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
[TBL] [Abstract][Full Text] [Related]
12. Intravenous immunoglobulin and plasmapheresis in acute humoral rejection: experience in renal allograft transplantation.
Lehrich RW; Rocha PN; Reinsmoen N; Greenberg A; Butterly DW; Howell DN; Smith SR
Hum Immunol; 2005 Apr; 66(4):350-8. PubMed ID: 15866697
[TBL] [Abstract][Full Text] [Related]
13. Plasmapheresis as rescue therapy in accelerated acute humoral rejection.
Abraham KA; Brown C; Conlon PJ; Donohoe J; Hickey DP; O'Neill D; Keogan MT; Dorman AM; Walshe J
J Clin Apher; 2003; 18(3):103-10. PubMed ID: 14569599
[TBL] [Abstract][Full Text] [Related]
14. Role of donor age and acute rejection episodes on long-term graft survival in cadaveric kidney transplantations.
Emiroğlu R; Yagmurdur MC; Karakayali F; Haberal C; Ozcelik U; Colak T; Haberal M
Transplant Proc; 2005 Sep; 37(7):2954-6. PubMed ID: 16213272
[TBL] [Abstract][Full Text] [Related]
15. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection.
Waiser J; Budde K; Schütz M; Liefeldt L; Rudolph B; Schönemann C; Neumayer HH; Lachmann N
Nephrol Dial Transplant; 2012 Mar; 27(3):1246-51. PubMed ID: 21852274
[TBL] [Abstract][Full Text] [Related]
16. A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection.
Mulley WR; Hudson FJ; Tait BD; Skene AM; Dowling JP; Kerr PG; Kanellis J
Transplantation; 2009 Jan; 87(2):286-9. PubMed ID: 19155986
[TBL] [Abstract][Full Text] [Related]
17. Therapy with plasmapheresis and intravenous immunoglobulin for acute humoral rejection in kidney transplantation.
Ibernón M; Gil-Vernet S; Carrera M; Serón D; Moreso F; Bestard O; Cruzado JM; Grinyó JM
Transplant Proc; 2005 Nov; 37(9):3743-5. PubMed ID: 16386524
[TBL] [Abstract][Full Text] [Related]
18. Alloantibodies and the outcome of cadaver kidney allografts.
Vasilescu ER; Ho EK; Colovai AI; Vlad G; Foca-Rodi A; Markowitz GS; D'Agati V; Hardy MA; Ratner LE; Suciu-Foca N
Hum Immunol; 2006 Aug; 67(8):597-604. PubMed ID: 16916655
[TBL] [Abstract][Full Text] [Related]
19. Current approaches to treatment of antibody-mediated rejection.
Jordan SC; Vo AA; Tyan D; Nast CC; Toyoda M
Pediatr Transplant; 2005 Jun; 9(3):408-15. PubMed ID: 15910400
[TBL] [Abstract][Full Text] [Related]
20. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection.
Fehr T; Rüsi B; Fischer A; Hopfer H; Wüthrich RP; Gaspert A
Transplantation; 2009 Jun; 87(12):1837-41. PubMed ID: 19543061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
